| Item type |
学術雑誌論文 / Journal Article_02(1) |
| 公開日 |
2025-05-16 |
| タイトル |
|
|
タイトル |
Efficacy of Cetuximab Combined with Paclitaxel in Patients with Recurrent Salivary Gland Carcinoma: A Retrospective Observational Study |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
Cetuximab |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
Epidermal growth factor receptor |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
Paclitaxel |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
Salivary duct carcinoma |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
Salivary gland carcinoma |
| 資源タイプ |
|
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 著者 |
Ryosuke, Sato
Ryota, Yuasa
Takumi, Kumai
Risa, Wakisaka
Hiroki, Komatsuda
Michihisa, Kono
Hidekiyo, Yamaki
Yoshiya, Ishida
Tetsuji, Wada
Miki, Takahara
Akihiro, Katada
|
| bibliographic_information |
en : ORL; journal for oto-rhino-laryngology and its related specialties
巻 86,
号 1,
p. 41-49,
発行日 2023-12-13
|
| ISSN |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0301-1569 |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
1423-0275 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1159/000534516 |
| item_1716186501932 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
38091970 |
| item_5_description_33 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Introduction: Due to the rarity and various histological types, a standard chemotherapy regimen for recurrent or metastatic salivary gland carcinoma (SGC) has not been established. Molecular-targeted therapy is a novel cancer therapy based on the expression of target molecules. However, few molecular-targeted therapy types have shown satisfactory efficacy for patients with SGC. Our study described promising results of epidermal growth factor receptor (EGFR)-targeting therapy with paclitaxel in patients with SGC.
Methods: The medical records of patients with recurrent SGC treated with weekly cetuximab combined with paclitaxel (Cmab-PTX) between December 2017 and December 2022 at our institutions were retrospectively analyzed.
Results: Seven patients with SGC received Cmab-PTX therapy. The median age was 76 years. All patients were high-grade histological types, and EGFR expression was positive in all examined patients. Cmab-PTX was administered for a median period of 20 months (range of 2-36 months). The overall responses were three with complete response, two with partial response, one with stable disease (>24 weeks), and one with progressive disease. The objective response and disease control rates were 71.4% and 85.7%, respectively. Progression-free survival ranged between 2 and 36 months (median 12 months), whereas overall survival ranged between 4 and 111 months (median 36 months). One patient experienced a grade 4 adverse event (neutropenia), which was conservatively manageable.
Conclusion: Although the treatment sensitivity of SGC with high-grade histological types is usually poor, Cmab-PTX could be a promising treatment regimen for recurrent SGC. Due to the rarity and various histological types, a standard chemotherapy regimen for recurrent or metastatic salivary gland carcinoma (SGC) has not been established. Molecular-targeted therapy is a novel cancer therapy based on the expression of target molecules. However, few molecular-targeted therapy types have shown satisfactory efficacy in patients with SGC. Our study described promising results of cetuximab (Cmab), epidermal growth factor receptor (EGFR)-targeting therapy with paclitaxel (PTX) in patients with SGC. Seven patients with SGC received Cmab-PTX therapy. The median age was 76 years. All patients were high-grade histological types, and EGFR expression was positive in all examined patients. Cmab-PTX was administered for a median period of 20 months. The overall responses were three with complete response, two with partial response, one with stable disease (>24 weeks), and one with progressive disease. The objective response rate was 71.4%. Progression-free survival ranged between 2 and 36 months (median 12 months), whereas overall survival ranged between 4 and 111 months (median 36 months). One patient experienced a grade 4 adverse event (neutropenia), which was conservatively manageable. Our study revealed a preferable objective response rate of Cmab-PTX for patients with high-grade SGC. Although the treatment sensitivity of SGC with high-grade histological types is usually poor, Cmab-PTX could be a promising treatment regimen for recurrent SGC. |
|
言語 |
en |
| 出版タイプ |
|
|
出版タイプ |
AM |
| item_5_textarea_42 |
|
|
|
en |
|
|
© 2023 S. Karger AG, Basel. |
38091970.pdf (1.8 MB)
